|
BE792533A
(fr)
|
1971-12-09 |
1973-06-08 |
Int Chem & Nuclear Corp |
Nouvelles pyrazolo (1,5a) pyrimidines et leur procede de preparation
|
|
JPS5868521A
(ja)
|
1981-10-16 |
1983-04-23 |
Hitachi Ltd |
流体継手の羽根車
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
|
US5994514A
(en)
|
1991-08-14 |
1999-11-30 |
Genentech, Inc. |
Immunoglobulin variants
|
|
EP0640094A1
(fr)
|
1992-04-24 |
1995-03-01 |
The Board Of Regents, The University Of Texas System |
Production recombinante de domaines semblables a l'immunoglobuline dans des cellules procaryotes
|
|
EP0714409A1
(fr)
|
1993-06-16 |
1996-06-05 |
Celltech Therapeutics Limited |
Anticorps
|
|
CA2143491C
(fr)
|
1994-03-01 |
2011-02-22 |
Yasumasa Ishida |
Nouveau peptide lie a l'apoptose humaine et adn codant ledit peptide
|
|
JP2778921B2
(ja)
|
1994-11-18 |
1998-07-23 |
三共株式会社 |
イミダゾピラゾール誘導体
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
KR101155191B1
(ko)
|
1999-01-15 |
2012-06-13 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
EP2360254A1
(fr)
|
1999-08-23 |
2011-08-24 |
Dana-Farber Cancer Institute, Inc. |
Essai de séléctions d'anti-pd1 anticorps et leurs utilisations
|
|
CA2383424C
(fr)
|
1999-08-23 |
2011-02-15 |
Gordon Freeman |
Nouvelles molecules b7-4 et leurs utilisations
|
|
DE60011100T2
(de)
|
1999-08-27 |
2005-06-16 |
Abbott Laboratories, Abbott Park |
Als cox-hemmer verwendbare sulfonylphenylpyrazol-verbindungen
|
|
DK1212327T3
(da)
|
1999-09-17 |
2003-12-15 |
Abbott Gmbh & Co Kg |
Pyrazolopyrimidiner som terapeutiske midler
|
|
CZ20023203A3
(cs)
|
2000-03-24 |
2003-08-13 |
Micromet Ag |
Multifunkční polypeptidy obsahující vazebné místo k epitopu receptorového komplexu NKG2D
|
|
AU5345901A
(en)
|
2000-04-13 |
2001-10-30 |
Univ Rockefeller |
Enhancement of antibody-mediated immune responses
|
|
US20020094989A1
(en)
|
2000-10-11 |
2002-07-18 |
Hale Jeffrey J. |
Pyrrolidine modulators of CCR5 chemokine receptor activity
|
|
CA2429042C
(fr)
|
2000-11-15 |
2012-09-25 |
Ono Pharmaceutical Co., Ltd. |
Souris deficientes en pd-1 et utilisation connexe
|
|
DE60143544D1
(de)
|
2000-12-12 |
2011-01-05 |
Medimmune Llc |
Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
|
|
AU2002231139B2
(en)
|
2000-12-21 |
2007-03-22 |
Bristol-Myers Squibb Company |
Thiazolyl inhibitors of tec family tyrosine kinases
|
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
MXPA03008031A
(es)
|
2001-03-07 |
2003-12-04 |
Merck Patent Gmbh |
Tecnologia de expresion para proteinas que contienen porcion de anticuerpo isotipo hibrida.
|
|
EP1370557B1
(fr)
|
2001-03-09 |
2005-11-16 |
Pfizer Products Inc. |
Composes de benzimidazole anti-inflammatoires
|
|
AR036993A1
(es)
|
2001-04-02 |
2004-10-20 |
Wyeth Corp |
Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
|
|
WO2003004497A1
(fr)
|
2001-07-05 |
2003-01-16 |
Sumitomo Pharmaceuticals Company, Limited |
Compose heterocyclique
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US8093357B2
(en)
|
2002-03-01 |
2012-01-10 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
JP4409430B2
(ja)
|
2002-07-03 |
2010-02-03 |
小野薬品工業株式会社 |
免疫賦活組成物
|
|
EP1572113B1
(fr)
|
2002-08-26 |
2017-05-17 |
Takeda Pharmaceutical Company Limited |
Compose modulateur de recepteur de calcium et utilisation associee
|
|
ZA200500782B
(en)
|
2002-08-26 |
2007-10-31 |
Takeda Pharmaceutical |
Calcium receptor modulating compound and use thereof
|
|
WO2004042017A2
(fr)
|
2002-10-31 |
2004-05-21 |
Genentech, Inc. |
Methodes et compositions pouvant augmenter la production d'anticorps
|
|
CN101899114A
(zh)
|
2002-12-23 |
2010-12-01 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
ES2897506T3
(es)
|
2003-01-09 |
2022-03-01 |
Macrogenics Inc |
Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos
|
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
US7563869B2
(en)
|
2003-01-23 |
2009-07-21 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to human PD-1
|
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
|
US20060183746A1
(en)
|
2003-06-04 |
2006-08-17 |
Currie Kevin S |
Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
|
|
US7405295B2
(en)
|
2003-06-04 |
2008-07-29 |
Cgi Pharmaceuticals, Inc. |
Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
|
|
WO2005005429A1
(fr)
|
2003-06-30 |
2005-01-20 |
Cellular Genomics, Inc. |
Certaines imidazo[1,2-a]pyrazin-8-ylamines substituees heterocycliques et methodes d'inhibition de la tyrosine kinase de bruton utilisant ces composes
|
|
JP2007500725A
(ja)
|
2003-07-29 |
2007-01-18 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
プロテインキナーゼ阻害剤としての化合物および組成物
|
|
EP2502935B1
(fr)
|
2003-08-22 |
2017-03-29 |
Biogen MA Inc. |
Anticorps améliorés dotés d'une fonction effectrice altérée et leurs procédés de fabrication
|
|
US20060134105A1
(en)
|
2004-10-21 |
2006-06-22 |
Xencor, Inc. |
IgG immunoglobulin variants with optimized effector function
|
|
WO2005047290A2
(fr)
|
2003-11-11 |
2005-05-26 |
Cellular Genomics Inc. |
Certaines imidazo[1,2-a]pyrazin-8-ylamines, procede de fabrication et methode d'utilisation
|
|
WO2005077981A2
(fr)
|
2003-12-22 |
2005-08-25 |
Xencor, Inc. |
Polypeptides fc a nouveaux sites de liaison de ligands fc
|
|
GB0400440D0
(en)
|
2004-01-09 |
2004-02-11 |
Isis Innovation |
Receptor modulators
|
|
JP4958555B2
(ja)
|
2004-09-22 |
2012-06-20 |
協和発酵キリン株式会社 |
安定化されたヒトＩｇＧ４抗体
|
|
WO2006053121A2
(fr)
|
2004-11-10 |
2006-05-18 |
Cgi Pharmaceuticals, Inc. |
Certaines imidazo[1,2-a] pyrazin-8-ylamines et les procédés de fabrication et d'utilisation correspondants
|
|
AU2005316668B2
(en)
|
2004-12-13 |
2012-09-06 |
Millennium Pharmaceuticals, Inc. |
Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors
|
|
RU2423351C2
(ru)
|
2004-12-16 |
2011-07-10 |
Вертекс Фармасьютикалз Инкорпорейтед |
Пирид-2-оны, применимые как ингибиторы протеинкиназ семейства тес для лечения воспалительных, пролиферативных и иммунологически-опосредованных заболеваний
|
|
TW200639163A
(en)
|
2005-02-04 |
2006-11-16 |
Genentech Inc |
RAF inhibitor compounds and methods
|
|
KR101357524B1
(ko)
|
2005-03-10 |
2014-02-03 |
질레드 코네티컷 인코포레이티드 |
특정 치환된 아미드, 그의 제조 방법, 및 사용 방법
|
|
CN117534755A
(zh)
|
2005-05-09 |
2024-02-09 |
小野药品工业株式会社 |
程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
|
|
BRPI0611766A2
(pt)
|
2005-06-08 |
2011-12-20 |
Dana Farber Cancer Inst Inc |
métodos e composições para o tratamento de infecções persistentes e cáncer por inibição da rota de morte celular programada
|
|
KR101888321B1
(ko)
|
2005-07-01 |
2018-08-13 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
US7786130B2
(en)
|
2005-08-29 |
2010-08-31 |
Vertex Pharmaceuticals Incorporated |
Pyridones useful as inhibitors of kinases
|
|
US7691885B2
(en)
|
2005-08-29 |
2010-04-06 |
Vertex Pharmaceuticals Incorporated |
Pyridones useful as inhibitors of kinases
|
|
WO2007026720A1
(fr)
|
2005-08-31 |
2007-03-08 |
Taisho Pharmaceutical Co., Ltd. |
Derive de pyrazole a noyau condense
|
|
JP5066516B2
(ja)
|
2005-09-01 |
2012-11-07 |
アステラス製薬株式会社 |
疼痛の治療に用いられるピリダジノン誘導体
|
|
CN101365682A
(zh)
|
2005-12-08 |
2009-02-11 |
千禧药品公司 |
具有激酶抑制活性的双环化合物
|
|
CN101421269A
(zh)
|
2006-01-13 |
2009-04-29 |
环状药物公司 |
酪氨酸激酶抑制剂及其用途
|
|
DE602007011415D1
(de)
|
2006-03-23 |
2011-02-03 |
Bioartic Neuroscience Ab |
Verbesserte protofibrilselektive antikörper und deren verwendung
|
|
CA2651153C
(fr)
|
2006-05-15 |
2014-04-29 |
Merck & Co., Inc. |
Composes bicycliques antidiabetiques
|
|
US8604031B2
(en)
|
2006-05-18 |
2013-12-10 |
Mannkind Corporation |
Intracellular kinase inhibitors
|
|
TWI398252B
(zh)
|
2006-05-26 |
2013-06-11 |
Novartis Ag |
吡咯并嘧啶化合物及其用途
|
|
CN101104640A
(zh)
|
2006-07-10 |
2008-01-16 |
苏州大学 |
抗人pd-l1单克隆抗体制备及应用
|
|
JP2010501540A
(ja)
|
2006-08-23 |
2010-01-21 |
ファイザー・プロダクツ・インク |
Ｇｓｋ−３阻害剤としてのピリミドン化合物
|
|
WO2008030448A1
(fr)
|
2006-09-07 |
2008-03-13 |
Millennium Pharmaceuticals, Inc. |
Dérivés de phénéthylamide avec une activité inhibitrice de kinase
|
|
PE20080839A1
(es)
|
2006-09-11 |
2008-08-23 |
Cgi Pharmaceuticals Inc |
Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
|
|
JP2010502751A
(ja)
|
2006-09-11 |
2010-01-28 |
シージーアイ ファーマシューティカルズ，インコーポレイティド |
キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法
|
|
AR063946A1
(es)
|
2006-09-11 |
2009-03-04 |
Cgi Pharmaceuticals Inc |
Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
|
|
PE20081370A1
(es)
|
2006-09-11 |
2008-11-28 |
Cgi Pharmaceuticals Inc |
Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
|
|
EP2532235A1
(fr)
|
2006-09-22 |
2012-12-12 |
Pharmacyclics, Inc. |
Inhibiteurs de la tyrosine kinase de bruton
|
|
CN101522026A
(zh)
|
2006-10-06 |
2009-09-02 |
Irm责任有限公司 |
蛋白激酶抑制剂及其应用方法
|
|
ES2403546T3
(es)
|
2006-11-03 |
2013-05-20 |
Pharmacyclics, Inc. |
Sonda de actividad de la tirosina-cinasa de Bruton y procedimiento de utilización
|
|
US8188272B2
(en)
|
2007-03-21 |
2012-05-29 |
Bristol-Myers Squibb Company |
Fused heterocyclic compounds useful as kinase modulators
|
|
KR20090130345A
(ko)
|
2007-05-04 |
2009-12-22 |
아이알엠 엘엘씨 |
Ｃ-ｋｉｔ 및 ｐｄｇｆｒ 키나제 억제제로서의 화합물 및 조성물
|
|
WO2008144253A1
(fr)
|
2007-05-14 |
2008-11-27 |
Irm Llc |
Inhibiteurs de la protéine kinase et procédé d'utilisation de ceux-ci
|
|
JP6071165B2
(ja)
|
2007-05-31 |
2017-02-01 |
ゲンマブ エー／エス |
安定なＩｇＧ４抗体
|
|
NZ600758A
(en)
|
2007-06-18 |
2013-09-27 |
Merck Sharp & Dohme |
Antibodies to human programmed death receptor pd-1
|
|
EP2195347A1
(fr)
|
2007-08-17 |
2010-06-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Méthode de traitement et de diagnostic de malignités hématologiques
|
|
CL2008002793A1
(es)
|
2007-09-20 |
2009-09-04 |
Cgi Pharmaceuticals Inc |
Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
|
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
TWI552752B
(zh)
|
2007-10-19 |
2016-10-11 |
賽基艾維洛米斯研究股份有限公司 |
雜芳基化合物及其用途
|
|
US7989465B2
(en)
|
2007-10-19 |
2011-08-02 |
Avila Therapeutics, Inc. |
4,6-disubstituted pyrimidines useful as kinase inhibitors
|
|
ES2444144T3
(es)
|
2007-10-23 |
2014-02-24 |
F. Hoffmann-La Roche Ag |
Nuevos inhibidores de quinasa
|
|
EP2229390B1
(fr)
|
2007-12-14 |
2014-04-09 |
F. Hoffmann-La Roche AG |
Dérivés innovants d'imidazoý1,2-a¨pyridine et d'imidazoý1,2-b¨pyridazine
|
|
NZ586916A
(en)
|
2008-02-05 |
2012-06-29 |
Hoffmann La Roche |
Novel pyridinones and pyridazinones
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
ES2554615T3
(es)
|
2008-05-06 |
2015-12-22 |
Gilead Connecticut, Inc. |
Amidas sustituidas, método de preparación y utilización como inhibidores de Btk
|
|
JP2011526299A
(ja)
|
2008-06-27 |
2011-10-06 |
アビラ セラピューティクス， インコーポレイテッド |
ヘテロアリール化合物およびそれらの使用
|
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
AU2009265813B2
(en)
|
2008-07-02 |
2014-04-10 |
F. Hoffmann-La Roche Ag |
Novel phenylpyrazinones as kinase inhibitors
|
|
CA2726460C
(fr)
|
2008-07-15 |
2017-02-21 |
F. Hoffmann-La Roche Ag |
Nouvelles phenyl-imidazopyridines et pyridazines
|
|
MX2011000661A
(es)
|
2008-07-16 |
2011-05-25 |
Pharmacyclics Inc |
Inhibidores de tirosina cinasa de bruton para el tratamiento de tumores solidos.
|
|
EP2307418B1
(fr)
|
2008-07-18 |
2014-03-12 |
F.Hoffmann-La Roche Ag |
Nouvelles phénylimidazopyrazines
|
|
JP2011529073A
(ja)
|
2008-07-24 |
2011-12-01 |
ブリストル−マイヤーズ スクイブ カンパニー |
キナーゼ調節因子として有用な縮合ヘテロ環化合物
|
|
JP2012510429A
(ja)
|
2008-08-25 |
2012-05-10 |
アンプリミューン、インコーポレーテッド |
Ｐｄ−１アンタゴニストおよびその使用方法
|
|
JP2012501654A
(ja)
|
2008-09-05 |
2012-01-26 |
アビラ セラピューティクス， インコーポレイテッド |
不可逆的インヒビターの設計のためのアルゴリズム
|
|
US8927697B2
(en)
|
2008-09-12 |
2015-01-06 |
Isis Innovation Limited |
PD-1 specific antibodies and uses thereof
|
|
JP5794917B2
(ja)
|
2008-09-12 |
2015-10-14 |
アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ |
Ｐｄ−１特異抗体およびその使用
|
|
US8552154B2
(en)
|
2008-09-26 |
2013-10-08 |
Emory University |
Anti-PD-L1 antibodies and uses therefor
|
|
KR101050829B1
(ko)
|
2008-10-02 |
2011-07-20 |
서울대학교산학협력단 |
항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
|
|
KR101686685B1
(ko)
|
2008-10-31 |
2016-12-14 |
제넨테크, 인크. |
피라졸로피리미딘 ｊａｋ 억제제 화합물 및 방법
|
|
US20120028981A1
(en)
|
2008-11-05 |
2012-02-02 |
Principia Biopharma Inc. |
Kinase Knockdown Via Electrophilically Enhanced Inhibitors
|
|
US8598174B2
(en)
|
2008-11-12 |
2013-12-03 |
Genetech, Inc. |
Pyridazinones, method of making, and method of use thereof
|
|
AU2009319701B2
(en)
|
2008-11-28 |
2014-10-09 |
Dana-Farber Cancer Institute, Inc. |
Methods for the treatment of infections and tumors
|
|
US8426428B2
(en)
|
2008-12-05 |
2013-04-23 |
Principia Biopharma, Inc. |
EGFR kinase knockdown via electrophilically enhanced inhibitors
|
|
CN102245640B
(zh)
|
2008-12-09 |
2014-12-31 |
霍夫曼-拉罗奇有限公司 |
抗-pd-l1抗体及它们用于增强t细胞功能的用途
|
|
WO2010068810A2
(fr)
|
2008-12-10 |
2010-06-17 |
Cgi Pharmaceuticals, Inc. |
Amides substitués, et leurs procédés de production et d'utilisation
|
|
WO2010068806A1
(fr)
|
2008-12-10 |
2010-06-17 |
Cgi Pharmaceuticals, Inc. |
Dérivés amides utilisés comme inhibiteurs de la btk dans le traitement des affections allergiques, auto-immunes et inflammatoires et dans le traitement du cancer
|
|
WO2010068788A1
(fr)
|
2008-12-10 |
2010-06-17 |
Cgi Pharmaceuticals, Inc. |
Amides hétérocycliques en tant qu'inhibiteurs de la btk
|
|
PE20110819A1
(es)
|
2008-12-19 |
2011-11-02 |
Bristol Myers Squibb Co |
Compuestos de carbazol carboxamida utiles como inhibidores de cinasa
|
|
US20100197924A1
(en)
|
2008-12-22 |
2010-08-05 |
Millennium Pharmaceuticals, Inc. |
Preparation of aminotetralin compounds
|
|
CA2748181C
(fr)
|
2009-01-06 |
2019-07-16 |
Nathanael S. Gray |
Composes pyrimido-diazepinone d'echafaudage de kinase et procedes de traitement de troubles
|
|
ES2629337T3
(es)
|
2009-02-09 |
2017-08-08 |
Inserm - Institut National De La Santé Et De La Recherche Médicale |
Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
|
|
US8299077B2
(en)
|
2009-03-02 |
2012-10-30 |
Roche Palo Alto Llc |
Inhibitors of Bruton's tyrosine kinase
|
|
CA2748414A1
(fr)
|
2009-04-24 |
2010-10-28 |
F. Hoffmann-La Roche Ag |
Inhibiteurs de la tyrosine kinase de bruton
|
|
JP5656976B2
(ja)
|
2009-04-29 |
2015-01-21 |
ローカス ファーマシューティカルズ インコーポレイテッド |
ピロロトリアジン化合物
|
|
JP2012529535A
(ja)
|
2009-06-12 |
2012-11-22 |
ブリストル−マイヤーズ スクイブ カンパニー |
キナーゼモジュレーターとして有用なニコチンアミド化合物
|
|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
|
WO2011019780A1
(fr)
|
2009-08-11 |
2011-02-17 |
Bristol-Myers Squibb Company |
Azaindazoles comme modulateurs de la kinase btk et leur utilisation
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
WO2011029043A1
(fr)
|
2009-09-04 |
2011-03-10 |
Biogen Idec Ma Inc. |
Inhibiteurs hétéroaryles de btk
|
|
TWI711610B
(zh)
|
2009-09-04 |
2020-12-01 |
美商百健Ｍａ公司 |
布魯頓氏酪胺酸激酶抑制劑
|
|
US7718662B1
(en)
|
2009-10-12 |
2010-05-18 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
|
|
EP2494062B1
(fr)
|
2009-10-28 |
2016-12-28 |
Janssen Biotech, Inc. |
Anticorps anti-glp-1r et leurs utilisations
|
|
US10053513B2
(en)
|
2009-11-30 |
2018-08-21 |
Janssen Biotech, Inc. |
Antibody Fc mutants with ablated effector functions
|
|
ES2826894T3
(es)
|
2010-02-19 |
2021-05-19 |
Xencor Inc |
Nuevas inmunoadhesinas CTLA4-IG
|
|
RU2012145183A
(ru)
|
2010-03-29 |
2014-05-10 |
Займворкс, Инк. |
Антитела с повышенной или пониженной эффекторной функцией
|
|
NZ604004A
(en)
|
2010-05-07 |
2014-06-27 |
Gilead Connecticut Inc |
Pyridone and aza-pyridone compounds and methods of use
|
|
DK2578585T3
(en)
|
2010-05-31 |
2016-11-14 |
Ono Pharmaceutical Co |
PURINONDERIVAT AS BTK kinase inhibitor
|
|
CA3240281A1
(fr)
|
2010-06-03 |
2011-12-08 |
Pharmacyclics Llc |
Utilisation d'inhibiteurs de la tyrosine-kinase de bruton dans le traitement du lymphome folliculaire
|
|
EP2582668B1
(fr)
|
2010-06-16 |
2016-01-13 |
Bristol-Myers Squibb Company |
Composes carboline carboxamide utiles en tant qu'inhibiteurs de kinase
|
|
LT2975042T
(lt)
|
2010-06-23 |
2019-01-25 |
Hanmi Science Co., Ltd. |
Naujieji kondensuoti pirimidino dariniai, skirti tirozino kinazės aktyvumo slopinimui
|
|
US20120053189A1
(en)
|
2010-06-28 |
2012-03-01 |
Pharmacyclics, Inc. |
Btk inhibitors for the treatment of immune mediated conditions
|
|
US20120100166A1
(en)
|
2010-07-15 |
2012-04-26 |
Zyngenia, Inc. |
Ang-2 Binding Complexes and Uses Thereof
|
|
AU2011289604C1
(en)
|
2010-08-10 |
2016-04-21 |
Celgene Avilomics Research, Inc. |
Besylate salt of a BTK inhibitor
|
|
AR082590A1
(es)
|
2010-08-12 |
2012-12-19 |
Hoffmann La Roche |
Inhibidores de la tirosina-quinasa de bruton
|
|
ES2537190T3
(es)
|
2010-09-01 |
2015-06-03 |
Gilead Connecticut, Inc. |
Piridazinonas, procedimiento de preparación y procedimientos de utilización de las mismas
|
|
ES2561277T3
(es)
|
2010-09-01 |
2016-02-25 |
Gilead Connecticut, Inc. |
Piridinonas/pirazinonas, procedimiento de preparación y procedimiento de utilización de las mismas
|
|
CN103429261A
(zh)
|
2010-12-22 |
2013-12-04 |
塞法隆澳大利亚股份有限公司 |
半寿期改进的修饰抗体
|
|
ES2692268T3
(es)
|
2011-03-29 |
2018-12-03 |
Roche Glycart Ag |
Variantes de Fc de anticuerpo
|
|
TR201810298T4
(tr)
|
2011-03-31 |
2018-08-27 |
Merck Sharp & Dohme |
İnsan programlı ölüm reseptörü PD-1'e karşı antikorların stabil formülasyonları ve ilgili tedaviler.
|
|
EP2694486B1
(fr)
|
2011-04-01 |
2018-01-10 |
University of Utah Research Foundation |
Analogues de n-(3-(pyrimidine-4-yl)phényl)acrylamide substitués en tant qu'inhibiteurs du récepteur tyrosine kinase btk
|
|
CA2760174A1
(fr)
|
2011-12-01 |
2013-06-01 |
Pharmascience Inc. |
Inhibiteurs de proteines kinases et leurs utilisations
|
|
EP2699264B1
(fr)
|
2011-04-20 |
2018-03-14 |
Medlmmune, LLC |
Anticorps et autres molécules qui se lient à b7-h1 et à pd-1
|
|
CN103596958A
(zh)
|
2011-04-20 |
2014-02-19 |
葛兰素集团有限公司 |
用作抗结核病化合物的四氢吡唑并[1,5-a]嘧啶
|
|
JP5859640B2
(ja)
|
2011-05-17 |
2016-02-10 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ブルトンチロシンキナーゼ阻害剤
|
|
WO2012158810A1
(fr)
|
2011-05-17 |
2012-11-22 |
Principia Biopharma Inc. |
Inhibiteurs de tyrosine kinase
|
|
SI2710005T1
(sl)
|
2011-05-17 |
2017-03-31 |
Principia Biopharma Inc. |
Zaviralci tirozinske kinaze
|
|
US9376438B2
(en)
|
2011-05-17 |
2016-06-28 |
Principia Biopharma, Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
|
RU2616881C2
(ru)
|
2011-06-06 |
2017-04-18 |
Ново Нордиск А/С |
Терапевтические антитела
|
|
BR112013030442B1
(pt)
|
2011-06-10 |
2021-11-09 |
Merck Patent Gmbh |
Compostos de pirimidina e piridina com atividade inibidora de btk, seus usos, composição, e kit
|
|
JP6120833B2
(ja)
|
2011-06-22 |
2017-04-26 |
インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル）Ｉｎｓｅｒｍ（Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅｌａ Ｓａｎｔｅ Ｅｔ Ｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌｅ） |
抗Ａｘｌ抗体及びその使用
|
|
KR20140058543A
(ko)
|
2011-07-08 |
2014-05-14 |
노파르티스 아게 |
신규 피롤로 피리미딘 유도체
|
|
TW202114735A
(zh)
|
2011-08-01 |
2021-04-16 |
美商建南德克公司 |
利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
|
|
PT2785375T
(pt)
|
2011-11-28 |
2020-10-29 |
Merck Patent Gmbh |
Anticorpos anti-pd-l1 e usos destes
|
|
DK2797888T3
(en)
|
2011-12-31 |
2016-09-19 |
Beigene Ltd |
Fused tricyclic compounds as RAF kinase inhibitors
|
|
CN113527469A
(zh)
|
2012-02-09 |
2021-10-22 |
中外制药株式会社 |
抗体的Fc区变异体
|
|
EP2844289B1
(fr)
|
2012-04-30 |
2019-07-17 |
MedImmune, LLC |
Molécules ayant une fonction effectrice réduite et des demi-vies allongées, compositions et utilisations de celles-ci
|
|
SG11201407190TA
(en)
|
2012-05-15 |
2014-12-30 |
Bristol Myers Squibb Co |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
|
BR112014029883B1
(pt)
|
2012-05-31 |
2023-10-24 |
Sorrento Therapeutics Inc. |
Anticorpo recombinante anti-pd-l1 e uso de um anticorpo recombinante anti-pd-l1
|
|
JP2015526409A
(ja)
|
2012-07-03 |
2015-09-10 |
ヤンセン・サイエンシズ・アイルランド・ユーシー |
Ｃ−末端及び中心エピトープａ−ベータ抗体
|
|
CN107892719B
(zh)
|
2012-10-04 |
2022-01-14 |
达纳－法伯癌症研究所公司 |
人单克隆抗-pd-l1抗体和使用方法
|
|
WO2014100490A1
(fr)
|
2012-12-19 |
2014-06-26 |
Adimab, Llc |
Analogues d'anticorps multivalents, et leurs procédés de préparation et d'utilisation
|
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
TWI635098B
(zh)
|
2013-02-01 |
2018-09-11 |
再生元醫藥公司 |
含嵌合恆定區之抗體
|
|
MY185881A
(en)
|
2013-02-20 |
2021-06-14 |
Regeneron Pharma |
Non-human animals with modified immunoglobulin heavy chain sequences
|
|
MX364591B
(es)
|
2013-03-15 |
2019-05-02 |
Regeneron Pharma |
Antagonistas de il-33 y usos de estos.
|
|
MX367918B
(es)
|
2013-04-25 |
2019-09-11 |
Beigene Ltd |
Compuestos heterociclicos fusionados como inhibidores de proteina quinasa.
|
|
WO2014193898A1
(fr)
*
|
2013-05-31 |
2014-12-04 |
Merck Sharp & Dohme Corp. |
Thérapies combinées contre le cancer
|
|
CA3175360C
(fr)
|
2013-05-31 |
2024-05-28 |
Sorrento Therapeutics, Inc. |
Proteines de liaison a l'antigene qui se lient a pd-1
|
|
SI3702373T1
(sl)
|
2013-09-13 |
2022-11-30 |
Beigene Switzerland Gmbh |
Protitelesa proti PD-1 in njihova uporaba kot terapevtiki in diagnostiki
|
|
AU2014339816B2
(en)
|
2013-10-25 |
2020-05-28 |
Pharmacyclics Llc |
Treatment using Bruton's tyrosine kinase inhibitors and immunotherapy
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
KR102003754B1
(ko)
|
2014-07-03 |
2019-07-25 |
베이진 엘티디 |
Pd-l1 항체와 이를 이용한 치료 및 진단
|
|
CN106687446B
(zh)
|
2014-07-18 |
2020-04-28 |
百济神州(北京)生物科技有限公司 |
作为t790m/wt-egfr的选择性和不可逆的激酶抑制剂的5-氨基-4-氨甲酰基-吡唑化合物及其用途
|
|
WO2016024231A1
(fr)
|
2014-08-11 |
2016-02-18 |
Acerta Pharma B.V. |
Combinaisons thérapeutiques d'un inhibiteur de btk, d'un inhibiteur de pi3k, d'un inhibiteur de jak-2, d'un inhibiteur de pd-1 et/ou d'un inhibiteur de pd-l1
|
|
EP3180343A1
(fr)
|
2014-08-14 |
2017-06-21 |
Assia Chemical Industries Ltd. |
Formes à l'état solide d'ibrutinib
|
|
TW201625304A
(zh)
|
2014-10-24 |
2016-07-16 |
美國禮來大藥廠 |
泌尿上皮癌之療法
|
|
WO2016087994A1
(fr)
|
2014-12-05 |
2016-06-09 |
Acerta Pharma B.V. |
Inhibiteurs de btk pour le traitement de tumeurs solides par modulation du micro-environnement tumoral
|
|
WO2016100914A1
(fr)
|
2014-12-18 |
2016-06-23 |
Gourlay Steven |
Traitement du pemphigus
|
|
PL3236943T3
(pl)
|
2014-12-24 |
2023-05-29 |
Principia Biopharma Inc. |
Kompozycje do krętniczo-czczego dostarczania leków
|
|
US9139653B1
(en)
|
2015-04-30 |
2015-09-22 |
Kymab Limited |
Anti-human OX40L antibodies and methods of treatment
|
|
EP4119559A1
(fr)
|
2015-04-15 |
2023-01-18 |
BeiGene, Ltd. |
Sels de maléate d'un inhibiteur de kinase b-raf, formes cristallines, procédés de préparation, et leurs utilisations
|
|
ES2789500T5
(es)
|
2015-05-29 |
2023-09-20 |
Hoffmann La Roche |
Procedimientos terapéuticos y de diagnóstico para el cáncer
|
|
WO2017024465A1
(fr)
|
2015-08-10 |
2017-02-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
Anticorps anti-pd-1
|
|
US20190022092A1
(en)
|
2015-09-15 |
2019-01-24 |
Acerta Pharma B.V. |
Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
|
|
EP3355875B1
(fr)
|
2015-10-01 |
2021-09-29 |
Gilead Sciences, Inc. |
Combinaison d'un inhibiteur de btk et d'un inhibiteur de point de contrôle pour le traitement de cancers
|
|
WO2017165491A1
(fr)
*
|
2016-03-24 |
2017-09-28 |
Millennium Pharmaceuticals, Inc. |
Utilisation d'un antagoniste de pd-1 et d'un inhibiteur de raf dans le traitement du cancer
|
|
NZ749997A
(en)
|
2016-07-05 |
2022-11-25 |
Beigene Ltd |
Combination of a pd-l antagonist and a raf inhibitor for treating cancer
|
|
TW202233628A
(zh)
|
2016-08-16 |
2022-09-01 |
英屬開曼群島商百濟神州有限公司 |
(s)-7-(1-丙烯醯基六氫吡啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氫吡唑並[1,5-a]嘧啶-3-甲醯胺的晶型、其製備和用途
|
|
ES2971881T3
(es)
|
2016-08-19 |
2024-06-10 |
Beigene Switzerland Gmbh |
Combinación de zanubrutinib con un anticuerpo anti-cd20 o anti-pd-1 para su uso en el tratamiento del cáncer
|
|
CN109790218B
(zh)
|
2016-08-26 |
2023-03-03 |
百济神州有限公司 |
抗tim-3抗体及其用途
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
US11202782B2
(en)
|
2016-09-27 |
2021-12-21 |
Beigene, Ltd. |
Treatment cancers using a combination comprising PARP inhibitors
|
|
RU2019114175A
(ru)
|
2016-10-14 |
2020-11-16 |
Ксенкор, Инк. |
Биспецифические гетеродимерные слитые белки, содержащие fc-слитые белки il-15/il-15ra и фрагменты антитела к pd-1
|
|
EP3573989A4
(fr)
|
2017-01-25 |
2020-11-18 |
Beigene, Ltd. |
Formes cristallines de (s) -7- (1- (but-2-ynoyl) pipéridin-4-yl) -2- (4-phénoxyphényl) -4, 5, 6, 7-tétrahy dropyrazolo [1, 5-a]pyrimidine-3-carboxamide, préparation et utilisations associées
|
|
US20200405879A1
(en)
|
2017-04-20 |
2020-12-31 |
Adc Therapeutics Sa |
Combination therapy
|
|
TW201906866A
(zh)
|
2017-06-26 |
2019-02-16 |
英屬開曼群島商百濟神州有限公司 |
酸性鞘磷脂酶缺乏症患者中異常骨狀況的治療
|
|
WO2019034009A1
(fr)
|
2017-08-12 |
2019-02-21 |
Beigene, Ltd. |
Inhibiteur de btk ayant une double sélectivité améliorée
|
|
CN111801334B
(zh)
|
2017-11-29 |
2023-06-09 |
百济神州瑞士有限责任公司 |
使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
|
|
WO2019157353A1
(fr)
|
2018-02-09 |
2019-08-15 |
Beigene, Ltd. |
Immunothérapie pour carcinome urothélial
|
|
GB201803746D0
(en)
|
2018-03-08 |
2018-04-25 |
Ultrahuman Eight Ltd |
PD1 binding agents
|